Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: A pilot study.

David TernantHélène MonjanelYann VenelCaroline Prunier-AeschFlavie ArbionPhilippe ColombatGilles PaintaudEmmanuel Gyan

Published in: British journal of clinical pharmacology (2019)

This study quantified for the first time the target-mediated elimination of rituximab in NHL patients and confirmed rituximab retention by antigen mass.

Keyphrases

diffuse large b cell lymphoma
hodgkin lymphoma
end stage renal disease
chronic lymphocytic leukemia
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors